Longevity Biotech Funding Tracker (49 deals)

Our funding tracker covering the Longevity Biotech Market

Below is the table listing all the deals. You may find our methodology at the end of this page.

And, if you want to gain a deeper understanding of the market and its current dynamics, get our report covering the Longevity Biotech Market.

Is longevity biotech really a $4 billion funding market?

Yes, longevity biotech has attracted at least $4.094 billion across 119 financings, but a small group of very large rounds makes the market look much richer than the typical company experiences.

The median financing is $10 million. The average is roughly $37.2 million, almost four times higher, because the top end stretches all the way to Neko Health's $700 million Series C and NewLimit's $435 million round.

Strip out deals above $50 million and only about $1.115 billion remains. Fewer than one in six financings clears $50 million, yet those deals absorb nearly three quarters of the known capital.

So the $4 billion headline is real. For a normal longevity startup, though, the more useful benchmark sits much closer to $10 million than $40 million.

Market measure	Result
Financings	119
Companies	96
Known/minimum capital	≥$4.094B
Median round	$10.0M
Average round	~$37.2M
Capital excluding >$50M rounds	~$1.115B
Capital excluding >$100M rounds	~$1.765B
>$50M rounds' share of capital	≥72.8%

How many longevity companies are investors actually backing?

The funded longevity market currently consists of 96 companies, and nearly four out of five appear only once during the whole period we studied.

Seventy-six companies have one qualifying financing, 17 have two, and only three raise three times or more.

Some younger companies simply haven't had time to come back for another round. Even allowing for that, the gap is large. Getting one longevity round funded is much more common than becoming a company investors finance repeatedly.

That gives us a better picture of the market than the raw 119-deal count. There is plenty of company formation and first-step financing, but a much smaller group keeps moving through the funding system.

Is most longevity funding going to just a few companies?

Yes. Longevity funding is heavily concentrated today: five companies hold 55.8% of the capital we measured, and ten hold 69.3%.

Neko Health sits far ahead with about $987.5 million raised across three financings during the period. NewLimit follows at $610 million, while Function Health reaches $351 million.

Below the leaders, the market falls away quickly. Roughly 31% of companies accumulate no more than $5 million during the period, while only around 16% get past $50 million.

Neko makes the concentration especially visible. No single Neko round represents more than 17.1% of market capital, but once we combine its three financings, the company alone reaches 24.1%.

Company	Financings	Capital in period
Neko Health	3	$987.5M
NewLimit	3	$610.0M
Function Health	2	$351.0M
BioAge Labs	1	$170.0M
Loyal	3	$167.0M
Corsera Health	2	≥$130.0M
Prenuvo	1	$120.0M
Lanserhof Group	1	$110.3M
Cognito Therapeutics	1	$105.0M
Tenpoint Therapeutics	1	$85.0M

What does a normal longevity funding round look like today?

A normal longevity round is still a single-digit or low-double-digit-million financing. The $5 million to $20 million range is by far the busiest part of the market, with 45 deals.

Another 28 financings come in below $5 million. Together, those two buckets contain more than 60% of all transactions.

The money tells a very different story. The 45 rounds between $5 million and $20 million contribute only about 10.6% of known capital. Ten financings of $100 million or more contribute roughly 59%.

For founders, that distinction is crucial. Billions are flowing into longevity, but investors are not routinely handing out nine-figure checks. Those checks belong to a tiny group that has reached a completely different level of development or commercial scale.

Deal size	Deals	Share of deals	Known capital
<$5M	28	23.5%	$67.6M
$5M–<$20M	45	37.8%	$433.8M
$20M–<$50M	18	15.1%	~$589.1M
$50M–<$100M	7	5.9%	~$500.0M
$100M+	10	8.4%	$2.428B
Unbucketable or unknown	11	9.2%	-
Total	119	100%	≥$4.094B

Which parts of longevity are investors putting serious money into?

Therapeutics and preventive-health platforms dominate longevity funding right now, taking roughly 84.5% of all known capital between them.

Longevity Therapeutics Developers lead with about $1.785 billion across 48 financings. Preventive Health Platforms are close behind at $1.674 billion despite having only 34 deals.

Then comes a steep drop. Healthy Aging Clinics attract about $239 million, Consumer Longevity Brands $230 million, Aging Research Platforms $103 million and Diagnostics Biomarker Companies just $63 million.

The two leading categories also get funded for different reasons. Therapeutics need money to push biological programs through increasingly expensive development. Preventive-health leaders are raising enormous sums to build clinics, hardware, testing infrastructure, software and geographic distribution.

The rest of longevity currently has much less evidence of companies reaching that kind of financing scale.

Why are preventive-health companies raising such huge rounds?

The biggest preventive-health companies now need capital for clinics, proprietary technology and expansion at the same time, which helps explain why this category absorbs 40.9% of longevity funding from only 28.6% of deals.

Neko Health is the clearest case. Its $700 million Series C is financing U.S. expansion of a model where the company designs its own hardware, software and clinical protocols. Neko said in July 2026 that more than 100,000 people had already used its scans in Sweden and the UK, with more than 350,000 people registered or waiting.

The company has since moved from plan to execution. In September 2026, Neko opened its first U.S. clinic in New York, where more than 25,000 people had joined the local waitlist before opening. This is now a physical healthcare rollout as well as a technology business.

Function Health is following a different version of the same pattern. Its $298 million Series B supports a health platform built around extensive laboratory testing, medical data and AI. Function said when announcing the round that hundreds of thousands of members were already using the service.

Most preventive-health startups never get checks like these. The category median is only $7 million. A few companies that prove they can scale pull the whole category sharply upward.

Why is longevity therapeutics attracting so much money?

Longevity therapeutics is absorbing serious capital because promising biology eventually has to survive the expensive transition into human development.

We measure about $1.785 billion across 48 therapeutic financings. NewLimit's $435 million Series C shows what happens near the top of that ladder: the company said the money would support its push to bring its first epigenetic-reprogramming medicine into human trials.

Corsera Health gives us another example at an earlier point. Its $80 million Series A arrived alongside the start of Phase 1 dosing for COR-1004, its PCSK9-targeting siRNA program. BioAge's $170 million Series D was similarly tied to clinical development, including Phase 2 work.

Regulation is evolving too. The FDA has recently launched an Expedited IND Pilot Program designed to speed the path toward first-in-human studies while keeping normal safety and scientific oversight. The agency still describes IND preparation, trial initiation and later pivotal development as a substantial development continuum.

That combination of scientific work, manufacturing, regulatory preparation and clinical trials produces much larger capital requirements than a typical software launch.

Is longevity funding mostly early-stage right now?

Yes by number of deals, while most of the money already sits much further up the funding ladder.

Seed accounts for 60 rounds and Series A another 21. Together they represent nearly 78% of financings where the stage is known.

Their capital share is far smaller. Series B alone attracts about $1.159 billion, while just four Series C financings contain another $1.34 billion.

The step-up in check size is sharp: the median rises from $5.4 million at Seed to $20 million at Series A, $45 million at Series B and about $270 million at Series C.

Longevity has a large early-stage population, but the funding dollars have already concentrated around the few companies that made it substantially further.

Stage	Deals	Median round	Known capital
Seed	60	$5.4M	$369.3M
Series A	21	$20.0M	$567.0M
Series B	13	$45.0M	$1.159B
Series C	4	$270.0M	$1.340B
Series D+	5	$66.0M	$377.5M
Growth Equity	1	$110.3M	$110.3M
Unknown	15	~$5.7M	$170.4M

Why do so few longevity companies make it to Series C?

The clearest break in the longevity funding ladder comes between Series B and Series C: we find 13 Series B financings and only four Series Cs.

Seed to Series A narrows heavily too, from 60 deals to 21. The Series B-to-C gap is more revealing commercially because this is where companies start moving from normal venture rounds into checks that can reach hundreds of millions.

We shouldn't read the ratio as a literal survival rate. These companies were founded in different years, and some recent Series B companies simply haven't had time to raise again.

Still, four Series Cs across the whole market is a tiny number. The longevity industry currently produces far more venture-backed experiments than companies investors are prepared to finance at mature scale.

Loyal shows how demanding that transition can be. After years of regulatory and clinical work in canine longevity, the company raised a $100 million Series C in 2026 to fund final regulatory work, scientific development and preparation for commercial launch.

How old are longevity companies when investors start writing big checks?

Large longevity rounds usually arrive after years of work: companies raising more than $50 million have a median age of around seven years, compared with roughly two years for companies raising below $5 million.

The progression by stage is intuitive. Seed financings happen at a median company age of about two years, Series A around five and a half, Series B around six and Series C around seven and a half.

Therapeutics fit that pattern particularly well because technical and clinical progress takes time.

Preventive-health platforms can move much faster. Their median age at financing is only two years, even though the category contains some of the largest checks in the market. Neko opened its first clinic in 2023 and was opening in the U.S. only a few years later.

Commercial proof can emerge much faster than clinical proof, and the financing data reflects that difference.

Is longevity funding going to a new generation of startups?

Yes. A large share of today's funded longevity companies were created recently, with the 2023 founding cohort the biggest in our research.

We count 20 reliable company records founded in 2023, followed by 12 from 2024 and another 12 from 2025. The 2021 and 2022 cohorts are also substantial.

So this market isn't simply recycling the same companies that were around before the current longevity wave. New businesses are entering quickly.

The striking part is what happens after formation. Recent cohorts are large while the Series C and growth-stage populations remain tiny. Longevity is creating fundable startups faster than it is creating mature funding candidates.

Are investors mostly financing new longevity startups or backing existing ones again?

Existing longevity companies take most of the money today: follow-on financings represent 67.2% of deals and roughly 88% of known capital.

First financings have a median size of about $6 million. Follow-ons come in much higher at $15 million.

Only 37.5% of the companies in our research register a first financing during the period. Once we look at dollars rather than company launches, the gap becomes even wider: first financings contribute about $368 million, compared with roughly $3.6 billion from follow-ons.

Repeat raisers reinforce the point. Only 20 of the 96 companies raise more than once, yet those 20 companies take about 61% of the market's measured capital.

Investors are still funding new longevity startups, but the big pools of money increasingly go toward companies that have already survived one or more financing tests.

Is longevity biotech mainly an American funding market?

The United States is still the broadest longevity funding market, while Europe's strong dollar share is heavily influenced by a few oversized winners.

North America represents 55.5% of deals and about 60.1% of known capital. The United States alone has 62 financings and close to 60% of the money we measured.

Europe contributes 28.6% of deals but 37.4% of capital. Sweden is the biggest reason: five Swedish financings account for roughly 24% of the entire market because Neko is headquartered there.

Asia-Pacific has 15 deals but only about 2% of measured capital. That figure understates the region somewhat because several Chinese financings have no exact disclosed amounts. Even so, the disclosed APAC rounds are nowhere near the largest U.S. and European checks.

For now, North America offers the deepest funding base. Europe's aggregate performance depends more heavily on individual companies.

Which longevity categories still struggle to raise big money?

Diagnostics, Aging Research Platforms and Healthy Aging Clinics all have active financing, but none currently has a broad group of companies raising at scale.

Diagnostics Biomarker Companies record seven deals and only about $63 million of known capital. There is no classified Series B-or-later financing in that group.

Aging Research Platforms reach around $103 million across eight deals, yet one company contributes close to half the category's capital.

Healthy Aging Clinics raise roughly $239 million across 12 financings, with the largest deal again supplying almost half the category total.

There are fundable companies in all three areas. What we don't see yet is a deep second layer of companies repeatedly raising $50 million-plus rounds.

That's a fairly big gap between having venture activity and having a mature scale-capital market.

Is longevity funding getting hotter, or do a few giant rounds make it look that way?

Longevity deal activity has been fairly steady, while monthly funding totals swing wildly whenever a mega-round lands.

Across the 33 completed months we studied, the market averages about 3.6 financings per month, with a median of three. The busiest month reaches 11 deals.

Capital is far more volatile. The median month contains roughly $54 million of known financing, while the peak month reaches at least $745.5 million.

As seen above, Neko's $700 million Series C explains almost all of that peak. A separate $435 million NewLimit financing similarly dominates another of the market's biggest months.

Deals keep happening at a reasonably regular pace, while the apparent funding boom arrives in bursts whenever one of the handful of scale companies raises.

Which investors keep coming back to longevity?

No small group of venture firms controls longevity funding today. Investor leadership is surprisingly fragmented.

Among 86 financings where we could identify a lead or co-lead, 99 different lead organizations appear after splitting syndicates. Only eight lead names show up more than once.

Lightspeed Venture Partners is the standout financially because two Neko rounds associated with its leadership represent a combined $960 million. Forerunner Ventures appears twice across roughly $148 million of preventive-health financing, while Left Lane Capital appears twice across about $130 million.

After that, recurring leadership drops quickly.

Unlike markets where a handful of specialist funds show up round after round, longevity currently draws a broad collection of investors without a dense core of repeat lead firms underwriting companies across multiple stages.

Do pharmaceutical and corporate investors matter in longevity?

Strategic investors matter most in longevity therapeutics, where corporate expertise can be almost as useful as the money.

We identify strategic participation in 19 financings, around 16% of the market. Their median round is about $16 million, compared with $9 million when no strategic investor is identified.

Therapeutics account for 11 of those 19 transactions.

Rubedo Life Sciences is a good example of why. Beiersdorf joined Rubedo's Series A through its Oscar & Paul corporate venture arm while also entering a multi-year partnership to work on compounds targeting cellular senescence. The relationship gives Rubedo more than a financial backer; it links the company with an established skincare R&D and commercialization platform.

BioAge's $170 million financing included both Lilly Ventures and Amgen Ventures, while NewLimit's investor group has also included Eli Lilly Ventures.

Corporate capital remains selective rather than widespread. Where it does appear, it tends to cluster around technologies that fit an existing pharmaceutical, healthcare or consumer-health capability.

What's missing from longevity funding right now?

The biggest missing piece in longevity funding is a broad middle-to-late-stage population.

We have 60 Seed rounds, 21 Series As and 13 Series Bs, followed by only four Series Cs. Just one Growth Equity transaction appears.

Diagnostics has no classified Series B-or-later round. Nearly four out of five companies appear only once. Several smaller categories rely on one company for roughly 40% to 50% of their capital.

Taken together, those gaps describe a market with plenty of experiments and a few spectacular winners, but still relatively few companies occupying the space between them.

That middle layer is what we'd expect to deepen if longevity matures over the next few years: more repeat financings, more Series B companies progressing to Series C, and less dependence on a handful of transactions for the headline capital total.

What can a normal longevity startup realistically expect to raise?

For most longevity startups today, a realistic venture round sits in the $5 million to $20 million range.

The market median is $10 million. Seed rounds have a median of $5.4 million, Series A rounds $20 million and Series B rounds $45 million.

Company-level figures lead to the same conclusion. The median company accumulates only about $9.4 million across the period we studied, even though the average exceeds $42 million.

Those numbers are far more representative than the giant financings readers usually see in headlines.

As pointed out above, nine-figure rounds belong to a very small scale-up population. A founder should treat Neko's $700 million, NewLimit's $435 million or Function Health's $298 million as evidence of what can happen after substantial de-risking or commercial traction, rather than as normal longevity funding benchmarks.

So what kind of funding market is longevity biotech today?

Longevity currently has a broad venture market at the bottom and a very small, extremely well-funded group at the top.

Most companies raise Seed or Series A money. Most rounds stay below $20 million. Dozens of companies receive funding, and recent founding cohorts remain large.

Then the funding curve changes dramatically. A few therapeutics companies reaching serious clinical development and a few preventive-health platforms reaching commercial scale can raise $100 million to $700 million at a time.

Only a small number of companies bridge those two parts of the market. That explains almost every apparent contradiction in the data: the $4.1 billion total alongside a $10 million median, dozens of funded startups alongside only four Series Cs, and regular monthly deal flow alongside huge swings in monthly capital.

For anyone trying to understand longevity funding today, the key question is how many companies can move from that crowded early-stage base into the much smaller group that investors are willing to finance repeatedly at scale.

What should we actually take away from the funding data?

Longevity is already a meaningful venture market, but the $4.094 billion headline is heavily shaped by a small number of exceptional financings. The typical round is still around $10 million.

The market has plenty of funded companies. Ninety-six businesses raised during the period, while only a small minority returned for multiple rounds and an even smaller group reached Series C-scale capital.

Therapeutics and preventive-health platforms are where serious money sits today. Together they take roughly 85% of known capital, although therapeutics spend heavily on scientific and clinical progression while preventive-health leaders increasingly fund physical infrastructure and expansion.

Follow-on capital drives the market. Existing portfolio companies receive the overwhelming majority of dollars, and the 20 repeat fundraisers we identified take roughly 61% of measured capital.

Investor interest is broad but not yet tightly organized. Dozens of different firms lead rounds, while only a handful repeatedly appear as lead investors.

The weak point is the middle of the ladder. Longevity produces many Seed companies and a few enormous winners, but the population moving consistently through Series B, Series C and growth funding remains thin.

That's the funding market as it stands now: relatively accessible at entry stage, much harder to keep scaling through.